{"success":true,"data":{"pressRelease":{"id":"18941","rtpr_id":"nPnb6kJf2a","ticker":"VNDA","exchange":"NASDAQ","all_tickers":["VNDA"],"title":"Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years","author":"PR Newswire","published_at":"2026-05-04T12:00:11.057Z","article_body":"Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years\n\nPR Newswire\n\nWASHINGTON, May 4, 2026\n\n * Consumers can now order NEREUS™ directly at\nnereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\nWASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)\n(Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now\ncommercially available across the United States for the prevention of vomiting\ninduced by motion in adults, marking the first new prescription medicine\napproved for this condition in more than 40 years. An innovative\ndirect-to-consumer order platform is now available through nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n.\n\n(https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html)\n\nMotion sickness affects an estimated 65 to 78 million Americans—roughly 25\nto 30 percent of adults—during everyday travel by car, plane, or boat. For\ndecades, patients have had no meaningful new treatment options. That changes\ntoday with NEREUS™, an oral neurokinin-1 (NK-1) receptor antagonist that\noffers a modern, targeted approach to a problem that has long lacked\ninnovation.\n\n\"Today marks an important milestone for the tens of millions of Americans who\nexperience motion sickness symptoms during common travel,\" said Mihael H.\nPolymeropoulos, M.D., President, CEO and Chairman of Vanda. \"NEREUS™ is a\nselective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1)\nreceptors that can block the vomiting center of the brain. We are excited to\nmake this innovative therapy available through both traditional pharmacy\nchannels and our new direct-to-consumer platform at nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n, giving travelers, families, and anyone affected by motion sickness\nconvenient access to a long-awaited solution.\"\n\nNEREUS™ is available now by prescription directly through nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\nand retail pharmacies nationwide. Through the dedicated direct-to-consumer\nportal at nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n, patients with a valid prescription can access NEREUS™ at a cash-pay price\nof just $85 per dose, a meaningful discount from the standard list price of\n$255 per dose.\n\nThroughout history, motion sickness has repeatedly undermined military\neffectiveness and human exploration. During Napoleon's 1798 Egyptian campaign,\nsoldiers in his newly formed camel corps—known as the \"ships of the\ndesert\"—suffered debilitating nausea and vomiting from the animals' swaying\ngait, rendering many unfit for battle and even affecting Napoleon himself. On\nD-Day in 1944, thousands of Allied paratroopers endured violent air sickness\nduring turbulent flights over the English Channel before they even reached\nNormandy. In the space age, nearly 70 percent of astronauts have faced space\nadaptation syndrome, a form of motion sickness that has challenged every major\nspace program since the 1960s. For more than four decades, no new\npharmacologic treatment emerged to address this ancient affliction—until\ntoday.\n\nMotion sickness may occur when the brain receives conflicting signals from the\neyes, inner ear, and body while on motion. This sensory mismatch is believed\nto trigger the release of substance P, which activates NK-1 receptors in the\ncentral nervous system and ultimately leads to nausea and vomiting. NEREUS™\nworks by blocking these receptors, interrupting the vomiting pathway.\n\nThe U.S. Food and Drug Administration approved NEREUS™ on December 30, 2025,\nfollowing two pivotal Phase 3 clinical trials—Motion Syros and Motion\nSerifos—conducted under real-world conditions on the open sea. Both studies\ndemonstrated that NEREUS™ significantly prevented vomiting compared to\nplacebo, confirming the drug's effectiveness in actual sea travel conditions.\nIt is the first new prescription option for people with history of motion\nsickness in over 40 years. It employs a novel mechanism as a selective,\nhigh-affinity antagonist of human substance P/NK-1 receptors. It offers simple\ndosing with just one or two capsules a day taken approximately an hour before\ntravel.\n\nThe commercial availability of NEREUS™ marks a historic milestone in\naddressing this highly prevalent physiological reaction to motion that has\nplagued humans for millennia.\n\nVisit nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\nto access the direct-to-consumer portal and learn more about NEREUS™.\n\nAbout Vanda Pharmaceuticals\n\nVanda is a leading global biopharmaceutical company focused on the development\nand commercialization of innovative therapies to address high unmet medical\nneeds and improve the lives of patients. For more on Vanda Pharmaceuticals\nInc., please visit www.vandapharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=1974087094&u=http%3A%2F%2Fwww.vandapharma.com%2F&a=www.vandapharma.com)\nand follow us on X @vandapharma.\n\nAbout NEREUS™\n\nIndication and Important Safety Information for NEREUS™ (tradipitant)\ncapsules.\n\nINDICATION\n\nNEREUS™ (NEER-ee-us) [tradipitant] is a prescription medication used for the\nprevention of vomiting induced by motion in adults.\n\nIMPORTANT SAFETY INFORMATION\n\nNEREUS™ may impair abilities required for driving a motor vehicle or\noperating heavy machinery. Combining NEREUS™ with sedatives or medications\nthat increase NEREUS™ levels may increase this effect. If use together\ncannot be avoided, your doctor may warn against driving or operating heavy\nmachinery.\n\nThe most common side effects associated with NEREUS™ include drowsiness,\nheadache, and fatigue.\n\nTell your healthcare provider about all of the medicines you're taking.\nStrong CYP3A4 inhibitors may increase NEREUS™ levels and the risk of side\neffects.\n\nTell your healthcare provider about all of your health conditions, including\nif you have liver or kidney problems, or if you are pregnant, planning to\nbecome pregnant, or breastfeeding. There are limited data on NEREUS™ use in\npregnant women.\n\nMonitor breastfed infants for drowsiness.\n\nThe safety and effectiveness of NEREUS™ for the prevention of vomiting\ninduced by motion in children have not been established.\n\nNEREUS™ is not recommended in patients with liver problems or severe kidney\nproblems.\n\nConsumer Important Safety Information\n\nYou are encouraged to report side effects of prescription drugs to the FDA. To\nreport side effects, contact Vanda Pharmaceuticals Inc. at 1-844-GO-VANDA\n(1-844-468-2632) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=923891091&u=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&a=www.fda.gov%2Fmedwatch)\n.\n\nFor more information, ask your healthcare provider or call 1-844-468-2632.\n\nThis information does not take the place of talking with your healthcare\nprovider for medical advice about your condition or treatment.\n\nDownload the full US Prescribing Information at nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n.\n\nNEREUS™ (tradipitant) is a neurokinin-1 receptor antagonist FDA approved for\nthe acute prevention of vomiting induced by motion in adults, and is currently\nin clinical development for a variety of other indications, including\ngastroparesis and the prevention of nausea and vomiting induced\nby GLP-1 receptor agonists. For full Prescribing Information and other\nresources, please visit nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n.\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nVarious statements in this press release, including, but not limited to\nstatements regarding the prevalence of motion sickness; the potential causes\nof motion sickness and the ways in which it may be triggered; and Vanda's\nfurther clinical development plans for NEREUS™ for various indications,\nincluding gastroparesis and vomiting induced by GLP-1 receptor agonists are\n\"forward-looking statements\" under the securities laws. All statements other\nthan statements of historical fact are statements that could be deemed\nforward-looking statements. Forward-looking statements are based upon current\nexpectations and assumptions that involve risks, changes in circumstances and\nuncertainties. Important factors that could cause actual results to differ\nmaterially from those reflected in Vanda's forward-looking statements include,\namong others, the accuracy of the estimates of the prevalence of motion\nsickness; Vanda's assumptions regarding the causes of motion sickness and the\nways in which it may be triggered; and Vanda's ability to continue to advance\ntradipitant in gastroparesis and the prevention of nausea and vomiting induced\nby GLP-1 receptor agonists. Therefore, no assurance can be given that the\nresults or developments anticipated by Vanda will be realized, or even if\nsubstantially realized, that they will have the expected consequences to, or\neffects on, Vanda. Forward-looking statements in this press release should be\nevaluated together with the various risks and uncertainties that affect\nVanda's business and market, particularly those identified in the \"Cautionary\nNote Regarding Forward-Looking Statements\", \"Risk Factors\" and \"Management's\nDiscussion and Analysis of Financial Condition and Results of Operations\"\nsections of Vanda's most recent Annual Report on Form 10-K, as updated by\nVanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K\nand other filings with the U.S. Securities and Exchange Commission, which are\navailable at www.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=1580372325&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov)\n.\n\nAll written and verbal forward-looking statements attributable to Vanda or any\nperson acting on its behalf are expressly qualified in their entirety by the\ncautionary statements contained or referred to herein. Vanda cautions\ninvestors not to rely too heavily on the forward-looking statements Vanda\nmakes or that are made on its behalf. The information in this press release is\nprovided only as of the date of this press release, and Vanda undertakes no\nobligation, and specifically declines any obligation, to update or revise\npublicly any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as required by law.\n\nCorporate Contact:\n\nKevin Moran\nSenior Vice President, Chief Financial Officer and Treasurer\nVanda Pharmaceuticals Inc.\n202-734-3400\npr@vandapharma.com (mailto:pr@vandapharma.com)\n\nJim Golden / Jack Kelleher / Dan Moore\nCollected Strategies\nVANDA-CS@collectedstrategies.com (mailto:VANDA-CS@collectedstrategies.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-us-commercial-availability-of-nereus-tradipitant-the-first-new-pharmacologic-treatment-for-people-with-motion-sickness-in-more-than-40-years-302760737.html\n(https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-us-commercial-availability-of-nereus-tradipitant-the-first-new-pharmacologic-treatment-for-people-with-motion-sickness-in-more-than-40-years-302760737.html)\n\nSOURCE Vanda Pharmaceuticals Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2090054/VandaLogo_v1.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPnb6kJf2a","title":"Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years","author":"PR Newswire","ticker":"VNDA","created":"2026-05-04T12:00:11.057Z","tickers":["VNDA"],"exchange":"NASDAQ","article_body":"Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years\n\nPR Newswire\n\nWASHINGTON, May 4, 2026\n\n * Consumers can now order NEREUS™ directly at\nnereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\nWASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda)\n(Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now\ncommercially available across the United States for the prevention of vomiting\ninduced by motion in adults, marking the first new prescription medicine\napproved for this condition in more than 40 years. An innovative\ndirect-to-consumer order platform is now available through nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n.\n\n(https://mma.prnewswire.com/media/2090054/VandaLogo_v1.html)\n\nMotion sickness affects an estimated 65 to 78 million Americans—roughly 25\nto 30 percent of adults—during everyday travel by car, plane, or boat. For\ndecades, patients have had no meaningful new treatment options. That changes\ntoday with NEREUS™, an oral neurokinin-1 (NK-1) receptor antagonist that\noffers a modern, targeted approach to a problem that has long lacked\ninnovation.\n\n\"Today marks an important milestone for the tens of millions of Americans who\nexperience motion sickness symptoms during common travel,\" said Mihael H.\nPolymeropoulos, M.D., President, CEO and Chairman of Vanda. \"NEREUS™ is a\nselective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1)\nreceptors that can block the vomiting center of the brain. We are excited to\nmake this innovative therapy available through both traditional pharmacy\nchannels and our new direct-to-consumer platform at nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n, giving travelers, families, and anyone affected by motion sickness\nconvenient access to a long-awaited solution.\"\n\nNEREUS™ is available now by prescription directly through nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\nand retail pharmacies nationwide. Through the dedicated direct-to-consumer\nportal at nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n, patients with a valid prescription can access NEREUS™ at a cash-pay price\nof just $85 per dose, a meaningful discount from the standard list price of\n$255 per dose.\n\nThroughout history, motion sickness has repeatedly undermined military\neffectiveness and human exploration. During Napoleon's 1798 Egyptian campaign,\nsoldiers in his newly formed camel corps—known as the \"ships of the\ndesert\"—suffered debilitating nausea and vomiting from the animals' swaying\ngait, rendering many unfit for battle and even affecting Napoleon himself. On\nD-Day in 1944, thousands of Allied paratroopers endured violent air sickness\nduring turbulent flights over the English Channel before they even reached\nNormandy. In the space age, nearly 70 percent of astronauts have faced space\nadaptation syndrome, a form of motion sickness that has challenged every major\nspace program since the 1960s. For more than four decades, no new\npharmacologic treatment emerged to address this ancient affliction—until\ntoday.\n\nMotion sickness may occur when the brain receives conflicting signals from the\neyes, inner ear, and body while on motion. This sensory mismatch is believed\nto trigger the release of substance P, which activates NK-1 receptors in the\ncentral nervous system and ultimately leads to nausea and vomiting. NEREUS™\nworks by blocking these receptors, interrupting the vomiting pathway.\n\nThe U.S. Food and Drug Administration approved NEREUS™ on December 30, 2025,\nfollowing two pivotal Phase 3 clinical trials—Motion Syros and Motion\nSerifos—conducted under real-world conditions on the open sea. Both studies\ndemonstrated that NEREUS™ significantly prevented vomiting compared to\nplacebo, confirming the drug's effectiveness in actual sea travel conditions.\nIt is the first new prescription option for people with history of motion\nsickness in over 40 years. It employs a novel mechanism as a selective,\nhigh-affinity antagonist of human substance P/NK-1 receptors. It offers simple\ndosing with just one or two capsules a day taken approximately an hour before\ntravel.\n\nThe commercial availability of NEREUS™ marks a historic milestone in\naddressing this highly prevalent physiological reaction to motion that has\nplagued humans for millennia.\n\nVisit nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\nto access the direct-to-consumer portal and learn more about NEREUS™.\n\nAbout Vanda Pharmaceuticals\n\nVanda is a leading global biopharmaceutical company focused on the development\nand commercialization of innovative therapies to address high unmet medical\nneeds and improve the lives of patients. For more on Vanda Pharmaceuticals\nInc., please visit www.vandapharma.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=1974087094&u=http%3A%2F%2Fwww.vandapharma.com%2F&a=www.vandapharma.com)\nand follow us on X @vandapharma.\n\nAbout NEREUS™\n\nIndication and Important Safety Information for NEREUS™ (tradipitant)\ncapsules.\n\nINDICATION\n\nNEREUS™ (NEER-ee-us) [tradipitant] is a prescription medication used for the\nprevention of vomiting induced by motion in adults.\n\nIMPORTANT SAFETY INFORMATION\n\nNEREUS™ may impair abilities required for driving a motor vehicle or\noperating heavy machinery. Combining NEREUS™ with sedatives or medications\nthat increase NEREUS™ levels may increase this effect. If use together\ncannot be avoided, your doctor may warn against driving or operating heavy\nmachinery.\n\nThe most common side effects associated with NEREUS™ include drowsiness,\nheadache, and fatigue.\n\nTell your healthcare provider about all of the medicines you're taking.\nStrong CYP3A4 inhibitors may increase NEREUS™ levels and the risk of side\neffects.\n\nTell your healthcare provider about all of your health conditions, including\nif you have liver or kidney problems, or if you are pregnant, planning to\nbecome pregnant, or breastfeeding. There are limited data on NEREUS™ use in\npregnant women.\n\nMonitor breastfed infants for drowsiness.\n\nThe safety and effectiveness of NEREUS™ for the prevention of vomiting\ninduced by motion in children have not been established.\n\nNEREUS™ is not recommended in patients with liver problems or severe kidney\nproblems.\n\nConsumer Important Safety Information\n\nYou are encouraged to report side effects of prescription drugs to the FDA. To\nreport side effects, contact Vanda Pharmaceuticals Inc. at 1-844-GO-VANDA\n(1-844-468-2632) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=923891091&u=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&a=www.fda.gov%2Fmedwatch)\n.\n\nFor more information, ask your healthcare provider or call 1-844-468-2632.\n\nThis information does not take the place of talking with your healthcare\nprovider for medical advice about your condition or treatment.\n\nDownload the full US Prescribing Information at nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n.\n\nNEREUS™ (tradipitant) is a neurokinin-1 receptor antagonist FDA approved for\nthe acute prevention of vomiting induced by motion in adults, and is currently\nin clinical development for a variety of other indications, including\ngastroparesis and the prevention of nausea and vomiting induced\nby GLP-1 receptor agonists. For full Prescribing Information and other\nresources, please visit nereus.us\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=2719576384&u=https%3A%2F%2Fnereus.us%2F&a=nereus.us)\n.\n\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nVarious statements in this press release, including, but not limited to\nstatements regarding the prevalence of motion sickness; the potential causes\nof motion sickness and the ways in which it may be triggered; and Vanda's\nfurther clinical development plans for NEREUS™ for various indications,\nincluding gastroparesis and vomiting induced by GLP-1 receptor agonists are\n\"forward-looking statements\" under the securities laws. All statements other\nthan statements of historical fact are statements that could be deemed\nforward-looking statements. Forward-looking statements are based upon current\nexpectations and assumptions that involve risks, changes in circumstances and\nuncertainties. Important factors that could cause actual results to differ\nmaterially from those reflected in Vanda's forward-looking statements include,\namong others, the accuracy of the estimates of the prevalence of motion\nsickness; Vanda's assumptions regarding the causes of motion sickness and the\nways in which it may be triggered; and Vanda's ability to continue to advance\ntradipitant in gastroparesis and the prevention of nausea and vomiting induced\nby GLP-1 receptor agonists. Therefore, no assurance can be given that the\nresults or developments anticipated by Vanda will be realized, or even if\nsubstantially realized, that they will have the expected consequences to, or\neffects on, Vanda. Forward-looking statements in this press release should be\nevaluated together with the various risks and uncertainties that affect\nVanda's business and market, particularly those identified in the \"Cautionary\nNote Regarding Forward-Looking Statements\", \"Risk Factors\" and \"Management's\nDiscussion and Analysis of Financial Condition and Results of Operations\"\nsections of Vanda's most recent Annual Report on Form 10-K, as updated by\nVanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K\nand other filings with the U.S. Securities and Exchange Commission, which are\navailable at www.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4679243-1&h=1580372325&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov)\n.\n\nAll written and verbal forward-looking statements attributable to Vanda or any\nperson acting on its behalf are expressly qualified in their entirety by the\ncautionary statements contained or referred to herein. Vanda cautions\ninvestors not to rely too heavily on the forward-looking statements Vanda\nmakes or that are made on its behalf. The information in this press release is\nprovided only as of the date of this press release, and Vanda undertakes no\nobligation, and specifically declines any obligation, to update or revise\npublicly any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as required by law.\n\nCorporate Contact:\n\nKevin Moran\nSenior Vice President, Chief Financial Officer and Treasurer\nVanda Pharmaceuticals Inc.\n202-734-3400\npr@vandapharma.com (mailto:pr@vandapharma.com)\n\nJim Golden / Jack Kelleher / Dan Moore\nCollected Strategies\nVANDA-CS@collectedstrategies.com (mailto:VANDA-CS@collectedstrategies.com)\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-us-commercial-availability-of-nereus-tradipitant-the-first-new-pharmacologic-treatment-for-people-with-motion-sickness-in-more-than-40-years-302760737.html\n(https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-us-commercial-availability-of-nereus-tradipitant-the-first-new-pharmacologic-treatment-for-people-with-motion-sickness-in-more-than-40-years-302760737.html)\n\nSOURCE Vanda Pharmaceuticals Inc.\n\n\n\nPhoto: \nhttps://mma.prnewswire.com/media/2090054/VandaLogo_v1.jpg\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-05-04T12:00:11.106434347Z","server_sent_at_ms":1777896011106},"received_at":"2026-05-04T12:00:11.196Z","source_url":"https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-us-commercial-availability-of-nereus-tradipitant-the-first-new-pharmacologic-treatment-for-people-with-motion-sickness-in-more-than-40-years-302760737.html"},"analysis":{"id":"13743","press_release_id":"18941","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Vanda Pharmaceuticals announced the U.S. commercial availability of NEREUS (tradipitant) for the prevention of motion sickness, marking the first new prescription treatment for this condition in over 40 years.\n\nThe drug is available via a direct-to-consumer platform and retail pharmacies, with a cash-pay price of $85 per dose compared to a standard list price of $255.\n\nThe FDA approved NEREUS on December 30, 2025, based on two pivotal Phase 3 trials that demonstrated significant prevention of vomiting in real-world sea travel conditions.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Vanda launches first-in-40-years motion sickness drug NEREUS with direct-to-consumer channel and discounted pricing."},"keyFigures":{"drugName":"NEREUS (tradipitant)","phaseOfTrial":"Phase 3","customDimensions":{"cash_pay_price":"$85 per dose","affected_population":"65 to 78 million Americans","standard_list_price":"$255 per dose"}},"quotedText":"Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel","namedEntities":{"people":[{"name":"Mihael H. Polymeropoulos","role":"President, CEO and Chairman"},{"name":"Kevin Moran","role":"Senior Vice President, Chief Financial Officer and Treasurer"}],"products":["NEREUS","tradipitant"],"companies":[{"name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA"},{"name":"Collected Strategies","relationship":"PR firm"}],"dollarAmounts":[{"amount":"$85 per dose","context":"cash-pay price"},{"amount":"$255 per dose","context":"standard list price"}]},"materialImpact":{"score":4,"reasoning":"Commercial launch of NEREUS, the first new treatment for motion sickness in over 40 years, addressing a market of 65-78 million Americans. Includes a direct-to-consumer strategy and aggressive pricing."},"tickerRelevance":{"others":[],"primary":"VNDA"},"globalImportance":40,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"major_product_launch","consumerFacing":true}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"Vanda Pharmaceuticals announced the U.S. commercial availability of NEREUS (tradipitant) for the prevention of motion sickness, marking the first new prescription treatment for this condition in over 40 years.\n\nThe drug is available via a direct-to-consumer platform and retail pharmacies, with a cash-pay price of $85 per dose compared to a standard list price of $255.\n\nThe FDA approved NEREUS on December 30, 2025, based on two pivotal Phase 3 trials that demonstrated significant prevention of vomiting in real-world sea travel conditions.","key_figures":{"drugName":"NEREUS (tradipitant)","phaseOfTrial":"Phase 3","customDimensions":{"cash_pay_price":"$85 per dose","affected_population":"65 to 78 million Americans","standard_list_price":"$255 per dose"}},"named_entities":{"people":[{"name":"Mihael H. Polymeropoulos","role":"President, CEO and Chairman"},{"name":"Kevin Moran","role":"Senior Vice President, Chief Financial Officer and Treasurer"}],"products":["NEREUS","tradipitant"],"companies":[{"name":"Vanda Pharmaceuticals Inc.","ticker":"VNDA"},{"name":"Collected Strategies","relationship":"PR firm"}],"dollarAmounts":[{"amount":"$85 per dose","context":"cash-pay price"},{"amount":"$255 per dose","context":"standard list price"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T14:51:32.906Z","global_importance":40,"audience_relevance":30,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"major_product_launch","consumerFacing":true}},"durationMs":146216,"modelName":"glm-4.7"}}